nodes	percent_of_prediction	percent_of_DWPC	metapath
Ifosfamide—germ cell cancer—bone cancer	0.622	1	CtDrD
Ifosfamide—CYP3A4—bone cancer	0.216	1	CbGaD
Ifosfamide—CYP2B6—Cisplatin—bone cancer	0.00411	0.416	CbGbCtD
Ifosfamide—CYP2B6—Doxorubicin—bone cancer	0.00275	0.279	CbGbCtD
Ifosfamide—CYP2C9—Cisplatin—bone cancer	0.00217	0.22	CbGbCtD
Ifosfamide—Cyclophosphamide—CYP3A4—bone cancer	0.00118	1	CrCbGaD
Ifosfamide—CYP2C18—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00116	0.0495	CbGpPWpGaD
Ifosfamide—CYP3A4—Doxorubicin—bone cancer	0.000845	0.0856	CbGbCtD
Ifosfamide—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000771	0.0329	CbGpPWpGaD
Ifosfamide—CYP2A6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000707	0.0302	CbGpPWpGaD
Ifosfamide—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00057	0.0244	CbGpPWpGaD
Ifosfamide—CYP2C18—Xenobiotics—CYP3A4—bone cancer	0.00056	0.0239	CbGpPWpGaD
Ifosfamide—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000558	0.0238	CbGpPWpGaD
Ifosfamide—CYP2C18—Metapathway biotransformation—CYP4V2—bone cancer	0.000499	0.0213	CbGpPWpGaD
Ifosfamide—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000483	0.0206	CbGpPWpGaD
Ifosfamide—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.000479	0.0205	CbGpPWpGaD
Ifosfamide—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000462	0.0197	CbGpPWpGaD
Ifosfamide—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000431	0.0184	CbGpPWpGaD
Ifosfamide—CYP2A6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000408	0.0174	CbGpPWpGaD
Ifosfamide—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000393	0.0168	CbGpPWpGaD
Ifosfamide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000376	0.016	CbGpPWpGaD
Ifosfamide—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000372	0.0159	CbGpPWpGaD
Ifosfamide—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000358	0.0153	CbGpPWpGaD
Ifosfamide—CYP2A6—Xenobiotics—CYP3A4—bone cancer	0.000341	0.0146	CbGpPWpGaD
Ifosfamide—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000332	0.0142	CbGpPWpGaD
Ifosfamide—CYP2A6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000328	0.014	CbGpPWpGaD
Ifosfamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000308	0.0132	CbGpPWpGaD
Ifosfamide—CYP2C18—Tryptophan metabolism—CYP3A4—bone cancer	0.000288	0.0123	CbGpPWpGaD
Ifosfamide—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00028	0.012	CbGpPWpGaD
Ifosfamide—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.000275	0.0118	CbGpPWpGaD
Ifosfamide—CYP2A6—Fluoropyrimidine Activity—DHFR—bone cancer	0.00027	0.0115	CbGpPWpGaD
Ifosfamide—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000269	0.0115	CbGpPWpGaD
Ifosfamide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000259	0.0111	CbGpPWpGaD
Ifosfamide—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000259	0.011	CbGpPWpGaD
Ifosfamide—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000245	0.0105	CbGpPWpGaD
Ifosfamide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000244	0.0104	CbGpPWpGaD
Ifosfamide—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.00024	0.0102	CbGpPWpGaD
Ifosfamide—CYP2A6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000234	0.01	CbGpPWpGaD
Ifosfamide—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000233	0.00995	CbGpPWpGaD
Ifosfamide—CYP2C18—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000232	0.00993	CbGpPWpGaD
Ifosfamide—CYP2C18—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000229	0.0098	CbGpPWpGaD
Ifosfamide—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000224	0.00957	CbGpPWpGaD
Ifosfamide—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000213	0.00908	CbGpPWpGaD
Ifosfamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000212	0.00907	CbGpPWpGaD
Ifosfamide—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000208	0.00888	CbGpPWpGaD
Ifosfamide—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000208	0.00887	CbGpPWpGaD
Ifosfamide—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.0002	0.00854	CbGpPWpGaD
Ifosfamide—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00019	0.0081	CbGpPWpGaD
Ifosfamide—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000189	0.00807	CbGpPWpGaD
Ifosfamide—CYP2C18—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000188	0.00805	CbGpPWpGaD
Ifosfamide—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000185	0.00792	CbGpPWpGaD
Ifosfamide—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000185	0.00789	CbGpPWpGaD
Ifosfamide—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000182	0.00779	CbGpPWpGaD
Ifosfamide—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.000181	0.00772	CbGpPWpGaD
Ifosfamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00018	0.00769	CbGpPWpGaD
Ifosfamide—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000169	0.00722	CbGpPWpGaD
Ifosfamide—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000167	0.00711	CbGpPWpGaD
Ifosfamide—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000163	0.00696	CbGpPWpGaD
Ifosfamide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000155	0.0066	CbGpPWpGaD
Ifosfamide—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000153	0.00651	CbGpPWpGaD
Ifosfamide—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000143	0.0061	CbGpPWpGaD
Ifosfamide—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000142	0.00605	CbGpPWpGaD
Ifosfamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00014	0.00598	CbGpPWpGaD
Ifosfamide—CYP2A6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00014	0.00597	CbGpPWpGaD
Ifosfamide—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000138	0.0059	CbGpPWpGaD
Ifosfamide—CYP2C18—Tryptophan metabolism—MDM2—bone cancer	0.000132	0.00564	CbGpPWpGaD
Ifosfamide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00013	0.00556	CbGpPWpGaD
Ifosfamide—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000125	0.00535	CbGpPWpGaD
Ifosfamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000124	0.0053	CbGpPWpGaD
Ifosfamide—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000121	0.00519	CbGpPWpGaD
Ifosfamide—CYP2C18—FOXA1 transcription factor network—JUN—bone cancer	0.000119	0.00508	CbGpPWpGaD
Ifosfamide—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000116	0.00493	CbGpPWpGaD
Ifosfamide—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000115	0.0049	CbGpPWpGaD
Ifosfamide—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000114	0.00488	CbGpPWpGaD
Ifosfamide—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000113	0.00482	CbGpPWpGaD
Ifosfamide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000112	0.00477	CbGpPWpGaD
Ifosfamide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000112	0.00476	CbGpPWpGaD
Ifosfamide—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00011	0.00471	CbGpPWpGaD
Ifosfamide—CYP2C18—Biological oxidations—CYP3A4—bone cancer	0.0001	0.00427	CbGpPWpGaD
Ifosfamide—CYP2C18—Metapathway biotransformation—CYP3A4—bone cancer	9.87e-05	0.00422	CbGpPWpGaD
Ifosfamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	9.68e-05	0.00413	CbGpPWpGaD
Ifosfamide—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	9.55e-05	0.00408	CbGpPWpGaD
Ifosfamide—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.27e-05	0.00396	CbGpPWpGaD
Ifosfamide—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.06e-05	0.00387	CbGpPWpGaD
Ifosfamide—Renal failure—Methotrexate—bone cancer	8.82e-05	0.000694	CcSEcCtD
Ifosfamide—Dysuria—Epirubicin—bone cancer	8.8e-05	0.000693	CcSEcCtD
Ifosfamide—Stomatitis—Methotrexate—bone cancer	8.74e-05	0.000689	CcSEcCtD
Ifosfamide—Conjunctivitis—Methotrexate—bone cancer	8.72e-05	0.000687	CcSEcCtD
Ifosfamide—Pollakiuria—Epirubicin—bone cancer	8.7e-05	0.000685	CcSEcCtD
Ifosfamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	8.64e-05	0.00369	CbGpPWpGaD
Ifosfamide—Feeling abnormal—Cisplatin—bone cancer	8.59e-05	0.000677	CcSEcCtD
Ifosfamide—CYP2C18—Biological oxidations—GSTP1—bone cancer	8.56e-05	0.00366	CbGpPWpGaD
Ifosfamide—Haematuria—Methotrexate—bone cancer	8.55e-05	0.000674	CcSEcCtD
Ifosfamide—Pancreatitis—Doxorubicin—bone cancer	8.54e-05	0.000673	CcSEcCtD
Ifosfamide—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	8.52e-05	0.00364	CbGpPWpGaD
Ifosfamide—Hyperglycaemia—Epirubicin—bone cancer	8.49e-05	0.000669	CcSEcCtD
Ifosfamide—Angina pectoris—Doxorubicin—bone cancer	8.49e-05	0.000668	CcSEcCtD
Ifosfamide—Hepatobiliary disease—Methotrexate—bone cancer	8.48e-05	0.000668	CcSEcCtD
Ifosfamide—CYP2C18—Metapathway biotransformation—GSTP1—bone cancer	8.44e-05	0.00361	CbGpPWpGaD
Ifosfamide—Pneumonia—Epirubicin—bone cancer	8.44e-05	0.000665	CcSEcCtD
Ifosfamide—Infestation NOS—Epirubicin—bone cancer	8.4e-05	0.000661	CcSEcCtD
Ifosfamide—Infestation—Epirubicin—bone cancer	8.4e-05	0.000661	CcSEcCtD
Ifosfamide—Agranulocytosis—Methotrexate—bone cancer	8.37e-05	0.000659	CcSEcCtD
Ifosfamide—Stevens-Johnson syndrome—Epirubicin—bone cancer	8.32e-05	0.000655	CcSEcCtD
Ifosfamide—Pancytopenia—Doxorubicin—bone cancer	8.27e-05	0.000652	CcSEcCtD
Ifosfamide—Renal failure—Epirubicin—bone cancer	8.25e-05	0.00065	CcSEcCtD
Ifosfamide—Body temperature increased—Cisplatin—bone cancer	8.24e-05	0.000649	CcSEcCtD
Ifosfamide—Neuropathy peripheral—Epirubicin—bone cancer	8.23e-05	0.000648	CcSEcCtD
Ifosfamide—Stomatitis—Epirubicin—bone cancer	8.18e-05	0.000644	CcSEcCtD
Ifosfamide—Conjunctivitis—Epirubicin—bone cancer	8.16e-05	0.000643	CcSEcCtD
Ifosfamide—Dysuria—Doxorubicin—bone cancer	8.15e-05	0.000642	CcSEcCtD
Ifosfamide—Haemoglobin—Methotrexate—bone cancer	8.09e-05	0.000637	CcSEcCtD
Ifosfamide—Haemorrhage—Methotrexate—bone cancer	8.05e-05	0.000634	CcSEcCtD
Ifosfamide—Hepatitis—Methotrexate—bone cancer	8.05e-05	0.000634	CcSEcCtD
Ifosfamide—Pollakiuria—Doxorubicin—bone cancer	8.05e-05	0.000634	CcSEcCtD
Ifosfamide—Haematuria—Epirubicin—bone cancer	8e-05	0.00063	CcSEcCtD
Ifosfamide—Urinary tract disorder—Methotrexate—bone cancer	7.95e-05	0.000626	CcSEcCtD
Ifosfamide—Hepatobiliary disease—Epirubicin—bone cancer	7.94e-05	0.000625	CcSEcCtD
Ifosfamide—Urethral disorder—Methotrexate—bone cancer	7.89e-05	0.000622	CcSEcCtD
Ifosfamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.88e-05	0.00336	CbGpPWpGaD
Ifosfamide—Hyperglycaemia—Doxorubicin—bone cancer	7.86e-05	0.000619	CcSEcCtD
Ifosfamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	7.84e-05	0.00335	CbGpPWpGaD
Ifosfamide—Agranulocytosis—Epirubicin—bone cancer	7.83e-05	0.000617	CcSEcCtD
Ifosfamide—Pneumonia—Doxorubicin—bone cancer	7.81e-05	0.000615	CcSEcCtD
Ifosfamide—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.77e-05	0.00332	CbGpPWpGaD
Ifosfamide—Infestation—Doxorubicin—bone cancer	7.77e-05	0.000612	CcSEcCtD
Ifosfamide—Infestation NOS—Doxorubicin—bone cancer	7.77e-05	0.000612	CcSEcCtD
Ifosfamide—Visual impairment—Methotrexate—bone cancer	7.76e-05	0.000611	CcSEcCtD
Ifosfamide—Stevens-Johnson syndrome—Doxorubicin—bone cancer	7.7e-05	0.000606	CcSEcCtD
Ifosfamide—Hypersensitivity—Cisplatin—bone cancer	7.68e-05	0.000605	CcSEcCtD
Ifosfamide—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	7.68e-05	0.00328	CbGpPWpGaD
Ifosfamide—Bradycardia—Epirubicin—bone cancer	7.67e-05	0.000604	CcSEcCtD
Ifosfamide—Renal failure—Doxorubicin—bone cancer	7.64e-05	0.000601	CcSEcCtD
Ifosfamide—Erythema multiforme—Methotrexate—bone cancer	7.61e-05	0.0006	CcSEcCtD
Ifosfamide—Neuropathy peripheral—Doxorubicin—bone cancer	7.61e-05	0.0006	CcSEcCtD
Ifosfamide—Haemoglobin—Epirubicin—bone cancer	7.57e-05	0.000597	CcSEcCtD
Ifosfamide—Stomatitis—Doxorubicin—bone cancer	7.57e-05	0.000596	CcSEcCtD
Ifosfamide—Conjunctivitis—Doxorubicin—bone cancer	7.55e-05	0.000595	CcSEcCtD
Ifosfamide—Haemorrhage—Epirubicin—bone cancer	7.54e-05	0.000593	CcSEcCtD
Ifosfamide—Hepatitis—Epirubicin—bone cancer	7.54e-05	0.000593	CcSEcCtD
Ifosfamide—Eye disorder—Methotrexate—bone cancer	7.53e-05	0.000593	CcSEcCtD
Ifosfamide—Tinnitus—Methotrexate—bone cancer	7.51e-05	0.000591	CcSEcCtD
Ifosfamide—Asthenia—Cisplatin—bone cancer	7.48e-05	0.000589	CcSEcCtD
Ifosfamide—Cardiac disorder—Methotrexate—bone cancer	7.47e-05	0.000589	CcSEcCtD
Ifosfamide—Urinary tract disorder—Epirubicin—bone cancer	7.44e-05	0.000586	CcSEcCtD
Ifosfamide—Haematuria—Doxorubicin—bone cancer	7.41e-05	0.000583	CcSEcCtD
Ifosfamide—Connective tissue disorder—Epirubicin—bone cancer	7.41e-05	0.000583	CcSEcCtD
Ifosfamide—Urethral disorder—Epirubicin—bone cancer	7.39e-05	0.000582	CcSEcCtD
Ifosfamide—Hepatobiliary disease—Doxorubicin—bone cancer	7.35e-05	0.000579	CcSEcCtD
Ifosfamide—Angiopathy—Methotrexate—bone cancer	7.31e-05	0.000575	CcSEcCtD
Ifosfamide—Immune system disorder—Methotrexate—bone cancer	7.27e-05	0.000573	CcSEcCtD
Ifosfamide—Visual impairment—Epirubicin—bone cancer	7.26e-05	0.000572	CcSEcCtD
Ifosfamide—Mediastinal disorder—Methotrexate—bone cancer	7.26e-05	0.000572	CcSEcCtD
Ifosfamide—Agranulocytosis—Doxorubicin—bone cancer	7.25e-05	0.000571	CcSEcCtD
Ifosfamide—Chills—Methotrexate—bone cancer	7.23e-05	0.000569	CcSEcCtD
Ifosfamide—Diarrhoea—Cisplatin—bone cancer	7.13e-05	0.000562	CcSEcCtD
Ifosfamide—Erythema multiforme—Epirubicin—bone cancer	7.13e-05	0.000561	CcSEcCtD
Ifosfamide—Alopecia—Methotrexate—bone cancer	7.12e-05	0.00056	CcSEcCtD
Ifosfamide—Bradycardia—Doxorubicin—bone cancer	7.1e-05	0.000559	CcSEcCtD
Ifosfamide—Mental disorder—Methotrexate—bone cancer	7.06e-05	0.000556	CcSEcCtD
Ifosfamide—Eye disorder—Epirubicin—bone cancer	7.04e-05	0.000555	CcSEcCtD
Ifosfamide—Tinnitus—Epirubicin—bone cancer	7.03e-05	0.000553	CcSEcCtD
Ifosfamide—Malnutrition—Methotrexate—bone cancer	7.01e-05	0.000552	CcSEcCtD
Ifosfamide—Erythema—Methotrexate—bone cancer	7.01e-05	0.000552	CcSEcCtD
Ifosfamide—Haemoglobin—Doxorubicin—bone cancer	7.01e-05	0.000552	CcSEcCtD
Ifosfamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	7e-05	0.00299	CbGpPWpGaD
Ifosfamide—Flushing—Epirubicin—bone cancer	6.99e-05	0.000551	CcSEcCtD
Ifosfamide—Cardiac disorder—Epirubicin—bone cancer	6.99e-05	0.000551	CcSEcCtD
Ifosfamide—Hepatitis—Doxorubicin—bone cancer	6.97e-05	0.000549	CcSEcCtD
Ifosfamide—Haemorrhage—Doxorubicin—bone cancer	6.97e-05	0.000549	CcSEcCtD
Ifosfamide—Urinary tract disorder—Doxorubicin—bone cancer	6.89e-05	0.000542	CcSEcCtD
Ifosfamide—Connective tissue disorder—Doxorubicin—bone cancer	6.85e-05	0.00054	CcSEcCtD
Ifosfamide—Angiopathy—Epirubicin—bone cancer	6.84e-05	0.000538	CcSEcCtD
Ifosfamide—Urethral disorder—Doxorubicin—bone cancer	6.84e-05	0.000538	CcSEcCtD
Ifosfamide—Immune system disorder—Epirubicin—bone cancer	6.81e-05	0.000536	CcSEcCtD
Ifosfamide—Mediastinal disorder—Epirubicin—bone cancer	6.79e-05	0.000535	CcSEcCtD
Ifosfamide—Chills—Epirubicin—bone cancer	6.76e-05	0.000533	CcSEcCtD
Ifosfamide—Arrhythmia—Epirubicin—bone cancer	6.73e-05	0.00053	CcSEcCtD
Ifosfamide—Visual impairment—Doxorubicin—bone cancer	6.72e-05	0.000529	CcSEcCtD
Ifosfamide—Alopecia—Epirubicin—bone cancer	6.66e-05	0.000524	CcSEcCtD
Ifosfamide—CYP3A7—Biological oxidations—CYP3A4—bone cancer	6.66e-05	0.00284	CbGpPWpGaD
Ifosfamide—Vomiting—Cisplatin—bone cancer	6.63e-05	0.000522	CcSEcCtD
Ifosfamide—Vision blurred—Methotrexate—bone cancer	6.61e-05	0.00052	CcSEcCtD
Ifosfamide—Mental disorder—Epirubicin—bone cancer	6.6e-05	0.00052	CcSEcCtD
Ifosfamide—Erythema multiforme—Doxorubicin—bone cancer	6.59e-05	0.000519	CcSEcCtD
Ifosfamide—Rash—Cisplatin—bone cancer	6.57e-05	0.000518	CcSEcCtD
Ifosfamide—Dermatitis—Cisplatin—bone cancer	6.57e-05	0.000517	CcSEcCtD
Ifosfamide—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	6.56e-05	0.0028	CbGpPWpGaD
Ifosfamide—Malnutrition—Epirubicin—bone cancer	6.56e-05	0.000517	CcSEcCtD
Ifosfamide—Erythema—Epirubicin—bone cancer	6.56e-05	0.000517	CcSEcCtD
Ifosfamide—Eye disorder—Doxorubicin—bone cancer	6.52e-05	0.000513	CcSEcCtD
Ifosfamide—Ill-defined disorder—Methotrexate—bone cancer	6.5e-05	0.000512	CcSEcCtD
Ifosfamide—Tinnitus—Doxorubicin—bone cancer	6.5e-05	0.000512	CcSEcCtD
Ifosfamide—Anaemia—Methotrexate—bone cancer	6.48e-05	0.00051	CcSEcCtD
Ifosfamide—Flushing—Doxorubicin—bone cancer	6.47e-05	0.00051	CcSEcCtD
Ifosfamide—Cardiac disorder—Doxorubicin—bone cancer	6.47e-05	0.00051	CcSEcCtD
Ifosfamide—PTGS1—Biological oxidations—CYP3A4—bone cancer	6.45e-05	0.00275	CbGpPWpGaD
Ifosfamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.38e-05	0.00273	CbGpPWpGaD
Ifosfamide—Angiopathy—Doxorubicin—bone cancer	6.33e-05	0.000498	CcSEcCtD
Ifosfamide—Malaise—Methotrexate—bone cancer	6.32e-05	0.000498	CcSEcCtD
Ifosfamide—Immune system disorder—Doxorubicin—bone cancer	6.3e-05	0.000496	CcSEcCtD
Ifosfamide—Vertigo—Methotrexate—bone cancer	6.3e-05	0.000496	CcSEcCtD
Ifosfamide—Mediastinal disorder—Doxorubicin—bone cancer	6.28e-05	0.000495	CcSEcCtD
Ifosfamide—Leukopenia—Methotrexate—bone cancer	6.28e-05	0.000494	CcSEcCtD
Ifosfamide—Chills—Doxorubicin—bone cancer	6.26e-05	0.000493	CcSEcCtD
Ifosfamide—Arrhythmia—Doxorubicin—bone cancer	6.23e-05	0.000491	CcSEcCtD
Ifosfamide—Nausea—Cisplatin—bone cancer	6.19e-05	0.000488	CcSEcCtD
Ifosfamide—Vision blurred—Epirubicin—bone cancer	6.18e-05	0.000487	CcSEcCtD
Ifosfamide—Alopecia—Doxorubicin—bone cancer	6.16e-05	0.000485	CcSEcCtD
Ifosfamide—Cough—Methotrexate—bone cancer	6.12e-05	0.000482	CcSEcCtD
Ifosfamide—Mental disorder—Doxorubicin—bone cancer	6.11e-05	0.000481	CcSEcCtD
Ifosfamide—CYP2A6—Biological oxidations—CYP3A4—bone cancer	6.1e-05	0.0026	CbGpPWpGaD
Ifosfamide—Ill-defined disorder—Epirubicin—bone cancer	6.09e-05	0.000479	CcSEcCtD
Ifosfamide—Convulsion—Methotrexate—bone cancer	6.07e-05	0.000478	CcSEcCtD
Ifosfamide—Erythema—Doxorubicin—bone cancer	6.07e-05	0.000478	CcSEcCtD
Ifosfamide—Malnutrition—Doxorubicin—bone cancer	6.07e-05	0.000478	CcSEcCtD
Ifosfamide—Anaemia—Epirubicin—bone cancer	6.06e-05	0.000478	CcSEcCtD
Ifosfamide—Agitation—Epirubicin—bone cancer	6.03e-05	0.000475	CcSEcCtD
Ifosfamide—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	6.03e-05	0.00257	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—NDUFA12—bone cancer	6e-05	0.00256	CbGpPWpGaD
Ifosfamide—Myalgia—Methotrexate—bone cancer	5.97e-05	0.00047	CcSEcCtD
Ifosfamide—Arthralgia—Methotrexate—bone cancer	5.97e-05	0.00047	CcSEcCtD
Ifosfamide—Chest pain—Methotrexate—bone cancer	5.97e-05	0.00047	CcSEcCtD
Ifosfamide—CYP2A6—NRF2 pathway—GSTP1—bone cancer	5.95e-05	0.00254	CbGpPWpGaD
Ifosfamide—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	5.95e-05	0.00254	CbGpPWpGaD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	5.93e-05	0.000467	CcSEcCtD
Ifosfamide—Malaise—Epirubicin—bone cancer	5.92e-05	0.000466	CcSEcCtD
Ifosfamide—Discomfort—Methotrexate—bone cancer	5.9e-05	0.000464	CcSEcCtD
Ifosfamide—Vertigo—Epirubicin—bone cancer	5.89e-05	0.000464	CcSEcCtD
Ifosfamide—Leukopenia—Epirubicin—bone cancer	5.87e-05	0.000462	CcSEcCtD
Ifosfamide—Palpitations—Epirubicin—bone cancer	5.8e-05	0.000457	CcSEcCtD
Ifosfamide—Confusional state—Methotrexate—bone cancer	5.77e-05	0.000454	CcSEcCtD
Ifosfamide—Cough—Epirubicin—bone cancer	5.72e-05	0.000451	CcSEcCtD
Ifosfamide—Anaphylactic shock—Methotrexate—bone cancer	5.72e-05	0.000451	CcSEcCtD
Ifosfamide—Vision blurred—Doxorubicin—bone cancer	5.72e-05	0.000451	CcSEcCtD
Ifosfamide—CYP3A7—Biological oxidations—GSTP1—bone cancer	5.69e-05	0.00243	CbGpPWpGaD
Ifosfamide—Convulsion—Epirubicin—bone cancer	5.68e-05	0.000448	CcSEcCtD
Ifosfamide—Infection—Methotrexate—bone cancer	5.68e-05	0.000448	CcSEcCtD
Ifosfamide—Hypertension—Epirubicin—bone cancer	5.66e-05	0.000446	CcSEcCtD
Ifosfamide—Ill-defined disorder—Doxorubicin—bone cancer	5.63e-05	0.000444	CcSEcCtD
Ifosfamide—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	5.61e-05	0.0024	CbGpPWpGaD
Ifosfamide—Nervous system disorder—Methotrexate—bone cancer	5.61e-05	0.000442	CcSEcCtD
Ifosfamide—Anaemia—Doxorubicin—bone cancer	5.61e-05	0.000442	CcSEcCtD
Ifosfamide—Thrombocytopenia—Methotrexate—bone cancer	5.6e-05	0.000441	CcSEcCtD
Ifosfamide—Chest pain—Epirubicin—bone cancer	5.59e-05	0.00044	CcSEcCtD
Ifosfamide—Myalgia—Epirubicin—bone cancer	5.59e-05	0.00044	CcSEcCtD
Ifosfamide—Arthralgia—Epirubicin—bone cancer	5.59e-05	0.00044	CcSEcCtD
Ifosfamide—Agitation—Doxorubicin—bone cancer	5.58e-05	0.000439	CcSEcCtD
Ifosfamide—Skin disorder—Methotrexate—bone cancer	5.56e-05	0.000438	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	5.55e-05	0.000437	CcSEcCtD
Ifosfamide—Hyperhidrosis—Methotrexate—bone cancer	5.53e-05	0.000436	CcSEcCtD
Ifosfamide—Discomfort—Epirubicin—bone cancer	5.52e-05	0.000435	CcSEcCtD
Ifosfamide—PTGS1—Biological oxidations—GSTP1—bone cancer	5.52e-05	0.00236	CbGpPWpGaD
Ifosfamide—Malaise—Doxorubicin—bone cancer	5.47e-05	0.000431	CcSEcCtD
Ifosfamide—Vertigo—Doxorubicin—bone cancer	5.45e-05	0.000429	CcSEcCtD
Ifosfamide—Anorexia—Methotrexate—bone cancer	5.45e-05	0.000429	CcSEcCtD
Ifosfamide—Leukopenia—Doxorubicin—bone cancer	5.43e-05	0.000428	CcSEcCtD
Ifosfamide—Confusional state—Epirubicin—bone cancer	5.4e-05	0.000425	CcSEcCtD
Ifosfamide—Palpitations—Doxorubicin—bone cancer	5.36e-05	0.000422	CcSEcCtD
Ifosfamide—Oedema—Epirubicin—bone cancer	5.35e-05	0.000422	CcSEcCtD
Ifosfamide—Anaphylactic shock—Epirubicin—bone cancer	5.35e-05	0.000422	CcSEcCtD
Ifosfamide—Hypotension—Methotrexate—bone cancer	5.35e-05	0.000421	CcSEcCtD
Ifosfamide—Infection—Epirubicin—bone cancer	5.32e-05	0.000419	CcSEcCtD
Ifosfamide—Cough—Doxorubicin—bone cancer	5.3e-05	0.000417	CcSEcCtD
Ifosfamide—Convulsion—Doxorubicin—bone cancer	5.26e-05	0.000414	CcSEcCtD
Ifosfamide—Nervous system disorder—Epirubicin—bone cancer	5.25e-05	0.000414	CcSEcCtD
Ifosfamide—Thrombocytopenia—Epirubicin—bone cancer	5.24e-05	0.000413	CcSEcCtD
Ifosfamide—Hypertension—Doxorubicin—bone cancer	5.24e-05	0.000413	CcSEcCtD
Ifosfamide—CYP2A6—Biological oxidations—GSTP1—bone cancer	5.22e-05	0.00223	CbGpPWpGaD
Ifosfamide—Musculoskeletal discomfort—Methotrexate—bone cancer	5.21e-05	0.000411	CcSEcCtD
Ifosfamide—Skin disorder—Epirubicin—bone cancer	5.2e-05	0.00041	CcSEcCtD
Ifosfamide—Hyperhidrosis—Epirubicin—bone cancer	5.18e-05	0.000408	CcSEcCtD
Ifosfamide—Arthralgia—Doxorubicin—bone cancer	5.17e-05	0.000407	CcSEcCtD
Ifosfamide—Chest pain—Doxorubicin—bone cancer	5.17e-05	0.000407	CcSEcCtD
Ifosfamide—Myalgia—Doxorubicin—bone cancer	5.17e-05	0.000407	CcSEcCtD
Ifosfamide—Paraesthesia—Methotrexate—bone cancer	5.14e-05	0.000405	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	5.13e-05	0.000404	CcSEcCtD
Ifosfamide—Discomfort—Doxorubicin—bone cancer	5.11e-05	0.000402	CcSEcCtD
Ifosfamide—Anorexia—Epirubicin—bone cancer	5.1e-05	0.000402	CcSEcCtD
Ifosfamide—Dyspnoea—Methotrexate—bone cancer	5.1e-05	0.000402	CcSEcCtD
Ifosfamide—Somnolence—Methotrexate—bone cancer	5.09e-05	0.000401	CcSEcCtD
Ifosfamide—Hypotension—Epirubicin—bone cancer	5e-05	0.000394	CcSEcCtD
Ifosfamide—Confusional state—Doxorubicin—bone cancer	5e-05	0.000393	CcSEcCtD
Ifosfamide—Decreased appetite—Methotrexate—bone cancer	4.97e-05	0.000392	CcSEcCtD
Ifosfamide—CYP2C18—Metabolism—NT5C3A—bone cancer	4.97e-05	0.00212	CbGpPWpGaD
Ifosfamide—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	4.96e-05	0.00212	CbGpPWpGaD
Ifosfamide—Anaphylactic shock—Doxorubicin—bone cancer	4.95e-05	0.00039	CcSEcCtD
Ifosfamide—Oedema—Doxorubicin—bone cancer	4.95e-05	0.00039	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Methotrexate—bone cancer	4.94e-05	0.000389	CcSEcCtD
Ifosfamide—Fatigue—Methotrexate—bone cancer	4.93e-05	0.000388	CcSEcCtD
Ifosfamide—CYP2B6—Biological oxidations—CYP3A4—bone cancer	4.92e-05	0.0021	CbGpPWpGaD
Ifosfamide—Infection—Doxorubicin—bone cancer	4.92e-05	0.000388	CcSEcCtD
Ifosfamide—Pain—Methotrexate—bone cancer	4.89e-05	0.000385	CcSEcCtD
Ifosfamide—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	4.89e-05	0.00209	CbGpPWpGaD
Ifosfamide—Musculoskeletal discomfort—Epirubicin—bone cancer	4.88e-05	0.000384	CcSEcCtD
Ifosfamide—Nervous system disorder—Doxorubicin—bone cancer	4.86e-05	0.000383	CcSEcCtD
Ifosfamide—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	4.85e-05	0.00207	CbGpPWpGaD
Ifosfamide—Thrombocytopenia—Doxorubicin—bone cancer	4.85e-05	0.000382	CcSEcCtD
Ifosfamide—Skin disorder—Doxorubicin—bone cancer	4.81e-05	0.000379	CcSEcCtD
Ifosfamide—CYP3A5—Biological oxidations—CYP3A4—bone cancer	4.81e-05	0.00205	CbGpPWpGaD
Ifosfamide—Paraesthesia—Epirubicin—bone cancer	4.81e-05	0.000379	CcSEcCtD
Ifosfamide—Hyperhidrosis—Doxorubicin—bone cancer	4.79e-05	0.000377	CcSEcCtD
Ifosfamide—Dyspnoea—Epirubicin—bone cancer	4.77e-05	0.000376	CcSEcCtD
Ifosfamide—Somnolence—Epirubicin—bone cancer	4.76e-05	0.000375	CcSEcCtD
Ifosfamide—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	4.74e-05	0.00203	CbGpPWpGaD
Ifosfamide—Anorexia—Doxorubicin—bone cancer	4.72e-05	0.000372	CcSEcCtD
Ifosfamide—Feeling abnormal—Methotrexate—bone cancer	4.71e-05	0.000371	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Methotrexate—bone cancer	4.68e-05	0.000368	CcSEcCtD
Ifosfamide—Decreased appetite—Epirubicin—bone cancer	4.65e-05	0.000367	CcSEcCtD
Ifosfamide—Hypotension—Doxorubicin—bone cancer	4.63e-05	0.000365	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Epirubicin—bone cancer	4.62e-05	0.000364	CcSEcCtD
Ifosfamide—Fatigue—Epirubicin—bone cancer	4.62e-05	0.000364	CcSEcCtD
Ifosfamide—Pain—Epirubicin—bone cancer	4.58e-05	0.000361	CcSEcCtD
Ifosfamide—Constipation—Epirubicin—bone cancer	4.58e-05	0.000361	CcSEcCtD
Ifosfamide—Urticaria—Methotrexate—bone cancer	4.55e-05	0.000358	CcSEcCtD
Ifosfamide—Body temperature increased—Methotrexate—bone cancer	4.52e-05	0.000356	CcSEcCtD
Ifosfamide—Abdominal pain—Methotrexate—bone cancer	4.52e-05	0.000356	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Doxorubicin—bone cancer	4.51e-05	0.000355	CcSEcCtD
Ifosfamide—Paraesthesia—Doxorubicin—bone cancer	4.45e-05	0.00035	CcSEcCtD
Ifosfamide—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	4.43e-05	0.00189	CbGpPWpGaD
Ifosfamide—Dyspnoea—Doxorubicin—bone cancer	4.42e-05	0.000348	CcSEcCtD
Ifosfamide—Feeling abnormal—Epirubicin—bone cancer	4.41e-05	0.000347	CcSEcCtD
Ifosfamide—Somnolence—Doxorubicin—bone cancer	4.4e-05	0.000347	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Epirubicin—bone cancer	4.38e-05	0.000345	CcSEcCtD
Ifosfamide—Decreased appetite—Doxorubicin—bone cancer	4.31e-05	0.000339	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Doxorubicin—bone cancer	4.28e-05	0.000337	CcSEcCtD
Ifosfamide—Fatigue—Doxorubicin—bone cancer	4.27e-05	0.000336	CcSEcCtD
Ifosfamide—Urticaria—Epirubicin—bone cancer	4.25e-05	0.000335	CcSEcCtD
Ifosfamide—Pain—Doxorubicin—bone cancer	4.24e-05	0.000334	CcSEcCtD
Ifosfamide—Constipation—Doxorubicin—bone cancer	4.24e-05	0.000334	CcSEcCtD
Ifosfamide—Body temperature increased—Epirubicin—bone cancer	4.23e-05	0.000333	CcSEcCtD
Ifosfamide—Abdominal pain—Epirubicin—bone cancer	4.23e-05	0.000333	CcSEcCtD
Ifosfamide—Hypersensitivity—Methotrexate—bone cancer	4.22e-05	0.000332	CcSEcCtD
Ifosfamide—CYP2B6—Biological oxidations—GSTP1—bone cancer	4.21e-05	0.0018	CbGpPWpGaD
Ifosfamide—CYP2C8—Biological oxidations—CYP3A4—bone cancer	4.17e-05	0.00178	CbGpPWpGaD
Ifosfamide—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	4.15e-05	0.00177	CbGpPWpGaD
Ifosfamide—CYP3A5—Biological oxidations—GSTP1—bone cancer	4.11e-05	0.00176	CbGpPWpGaD
Ifosfamide—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	4.11e-05	0.00175	CbGpPWpGaD
Ifosfamide—Asthenia—Methotrexate—bone cancer	4.1e-05	0.000323	CcSEcCtD
Ifosfamide—Feeling abnormal—Doxorubicin—bone cancer	4.08e-05	0.000322	CcSEcCtD
Ifosfamide—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	4.06e-05	0.00173	CbGpPWpGaD
Ifosfamide—Gastrointestinal pain—Doxorubicin—bone cancer	4.05e-05	0.000319	CcSEcCtD
Ifosfamide—Pruritus—Methotrexate—bone cancer	4.05e-05	0.000319	CcSEcCtD
Ifosfamide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	4.04e-05	0.00172	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—NDUFA12—bone cancer	3.99e-05	0.0017	CbGpPWpGaD
Ifosfamide—Hypersensitivity—Epirubicin—bone cancer	3.94e-05	0.000311	CcSEcCtD
Ifosfamide—Urticaria—Doxorubicin—bone cancer	3.94e-05	0.00031	CcSEcCtD
Ifosfamide—Body temperature increased—Doxorubicin—bone cancer	3.92e-05	0.000308	CcSEcCtD
Ifosfamide—Abdominal pain—Doxorubicin—bone cancer	3.92e-05	0.000308	CcSEcCtD
Ifosfamide—Diarrhoea—Methotrexate—bone cancer	3.91e-05	0.000308	CcSEcCtD
Ifosfamide—PTGS1—Metabolism—NDUFA12—bone cancer	3.87e-05	0.00165	CbGpPWpGaD
Ifosfamide—Asthenia—Epirubicin—bone cancer	3.84e-05	0.000303	CcSEcCtD
Ifosfamide—Pruritus—Epirubicin—bone cancer	3.79e-05	0.000298	CcSEcCtD
Ifosfamide—Dizziness—Methotrexate—bone cancer	3.78e-05	0.000298	CcSEcCtD
Ifosfamide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	3.72e-05	0.00159	CbGpPWpGaD
Ifosfamide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	3.67e-05	0.00157	CbGpPWpGaD
Ifosfamide—Diarrhoea—Epirubicin—bone cancer	3.66e-05	0.000289	CcSEcCtD
Ifosfamide—CYP2A6—Metabolism—NDUFA12—bone cancer	3.66e-05	0.00156	CbGpPWpGaD
Ifosfamide—Hypersensitivity—Doxorubicin—bone cancer	3.65e-05	0.000287	CcSEcCtD
Ifosfamide—Vomiting—Methotrexate—bone cancer	3.64e-05	0.000286	CcSEcCtD
Ifosfamide—Rash—Methotrexate—bone cancer	3.61e-05	0.000284	CcSEcCtD
Ifosfamide—Dermatitis—Methotrexate—bone cancer	3.6e-05	0.000284	CcSEcCtD
Ifosfamide—CYP2C8—Biological oxidations—GSTP1—bone cancer	3.56e-05	0.00152	CbGpPWpGaD
Ifosfamide—Asthenia—Doxorubicin—bone cancer	3.55e-05	0.00028	CcSEcCtD
Ifosfamide—Dizziness—Epirubicin—bone cancer	3.54e-05	0.000279	CcSEcCtD
Ifosfamide—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	3.51e-05	0.0015	CbGpPWpGaD
Ifosfamide—Pruritus—Doxorubicin—bone cancer	3.51e-05	0.000276	CcSEcCtD
Ifosfamide—Vomiting—Epirubicin—bone cancer	3.4e-05	0.000268	CcSEcCtD
Ifosfamide—Nausea—Methotrexate—bone cancer	3.4e-05	0.000268	CcSEcCtD
Ifosfamide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	3.39e-05	0.00145	CbGpPWpGaD
Ifosfamide—Diarrhoea—Doxorubicin—bone cancer	3.39e-05	0.000267	CcSEcCtD
Ifosfamide—Rash—Epirubicin—bone cancer	3.38e-05	0.000266	CcSEcCtD
Ifosfamide—Dermatitis—Epirubicin—bone cancer	3.37e-05	0.000266	CcSEcCtD
Ifosfamide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	3.34e-05	0.00143	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—NT5C3A—bone cancer	3.31e-05	0.00141	CbGpPWpGaD
Ifosfamide—Dizziness—Doxorubicin—bone cancer	3.28e-05	0.000258	CcSEcCtD
Ifosfamide—PTGS1—Metabolism—NT5C3A—bone cancer	3.2e-05	0.00137	CbGpPWpGaD
Ifosfamide—CYP2C19—Biological oxidations—GSTP1—bone cancer	3.18e-05	0.00136	CbGpPWpGaD
Ifosfamide—Nausea—Epirubicin—bone cancer	3.18e-05	0.00025	CcSEcCtD
Ifosfamide—Vomiting—Doxorubicin—bone cancer	3.15e-05	0.000248	CcSEcCtD
Ifosfamide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	3.14e-05	0.00134	CbGpPWpGaD
Ifosfamide—Rash—Doxorubicin—bone cancer	3.12e-05	0.000246	CcSEcCtD
Ifosfamide—Dermatitis—Doxorubicin—bone cancer	3.12e-05	0.000246	CcSEcCtD
Ifosfamide—CYP2A6—Metabolism—NT5C3A—bone cancer	3.03e-05	0.00129	CbGpPWpGaD
Ifosfamide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.95e-05	0.00126	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—NDUFA12—bone cancer	2.95e-05	0.00126	CbGpPWpGaD
Ifosfamide—Nausea—Doxorubicin—bone cancer	2.94e-05	0.000232	CcSEcCtD
Ifosfamide—CYP2C9—Biological oxidations—GSTP1—bone cancer	2.9e-05	0.00124	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—NDUFA12—bone cancer	2.88e-05	0.00123	CbGpPWpGaD
Ifosfamide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	2.86e-05	0.00122	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—NDUFA12—bone cancer	2.5e-05	0.00107	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—NT5C3A—bone cancer	2.44e-05	0.00104	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—NT5C3A—bone cancer	2.39e-05	0.00102	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—NDUFA12—bone cancer	2.23e-05	0.000952	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—ENO2—bone cancer	2.18e-05	0.00093	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—NT5C3A—bone cancer	2.07e-05	0.000884	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—NDUFA12—bone cancer	2.03e-05	0.000868	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—DHFR—bone cancer	2.02e-05	0.000863	CbGpPWpGaD
Ifosfamide—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.91e-05	0.000817	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—GNA11—bone cancer	1.89e-05	0.000806	CbGpPWpGaD
Ifosfamide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.89e-05	0.000806	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—NT5C3A—bone cancer	1.85e-05	0.000789	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—CYP3A4—bone cancer	1.71e-05	0.000731	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—NT5C3A—bone cancer	1.68e-05	0.000719	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—GSTP1—bone cancer	1.46e-05	0.000625	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—ENO2—bone cancer	1.45e-05	0.000618	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—ENO2—bone cancer	1.4e-05	0.000599	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—DHFR—bone cancer	1.34e-05	0.000574	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—NDUFA12—bone cancer	1.34e-05	0.000572	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—ENO2—bone cancer	1.33e-05	0.000567	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—DHFR—bone cancer	1.3e-05	0.000556	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—GNA11—bone cancer	1.26e-05	0.000536	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—DHFR—bone cancer	1.23e-05	0.000526	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—GNA11—bone cancer	1.22e-05	0.00052	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—GNA11—bone cancer	1.15e-05	0.000491	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—CYP3A4—bone cancer	1.14e-05	0.000486	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—NT5C3A—bone cancer	1.11e-05	0.000474	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—CYP3A4—bone cancer	1.1e-05	0.000471	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.1e-05	0.000469	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—ENO2—bone cancer	1.07e-05	0.000457	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—ENO2—bone cancer	1.05e-05	0.000447	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—CYP3A4—bone cancer	1.04e-05	0.000445	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—DHFR—bone cancer	9.93e-06	0.000424	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—GSTP1—bone cancer	9.73e-06	0.000416	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—DHFR—bone cancer	9.71e-06	0.000415	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—GSTP1—bone cancer	9.44e-06	0.000403	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—GNA11—bone cancer	9.28e-06	0.000396	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—GNA11—bone cancer	9.07e-06	0.000387	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—ENO2—bone cancer	9.07e-06	0.000387	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—GSTP1—bone cancer	8.92e-06	0.000381	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—CYP3A4—bone cancer	8.42e-06	0.000359	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—DHFR—bone cancer	8.41e-06	0.000359	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—CYP3A4—bone cancer	8.23e-06	0.000351	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—ENO2—bone cancer	8.09e-06	0.000345	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—GNA11—bone cancer	7.86e-06	0.000336	CbGpPWpGaD
Ifosfamide—CYP2C18—Metabolism—PTGS2—bone cancer	7.59e-06	0.000324	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—DHFR—bone cancer	7.51e-06	0.000321	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—ENO2—bone cancer	7.38e-06	0.000315	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—GSTP1—bone cancer	7.2e-06	0.000307	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—CYP3A4—bone cancer	7.13e-06	0.000304	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.09e-06	0.000303	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—GSTP1—bone cancer	7.04e-06	0.0003	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—GNA11—bone cancer	7.02e-06	0.0003	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—DHFR—bone cancer	6.84e-06	0.000292	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—GNA11—bone cancer	6.4e-06	0.000273	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—CYP3A4—bone cancer	6.36e-06	0.000272	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.33e-06	0.00027	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—GSTP1—bone cancer	6.09e-06	0.00026	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—CYP3A4—bone cancer	5.8e-06	0.000248	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.77e-06	0.000246	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—GSTP1—bone cancer	5.44e-06	0.000232	CbGpPWpGaD
Ifosfamide—CYP3A7—Metabolism—PTGS2—bone cancer	5.04e-06	0.000215	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—GSTP1—bone cancer	4.96e-06	0.000212	CbGpPWpGaD
Ifosfamide—PTGS1—Metabolism—PTGS2—bone cancer	4.89e-06	0.000209	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—ENO2—bone cancer	4.87e-06	0.000208	CbGpPWpGaD
Ifosfamide—CYP2A6—Metabolism—PTGS2—bone cancer	4.62e-06	0.000197	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—DHFR—bone cancer	4.51e-06	0.000193	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—GNA11—bone cancer	4.22e-06	0.00018	CbGpPWpGaD
Ifosfamide—CYP2B6—Metabolism—PTGS2—bone cancer	3.73e-06	0.000159	CbGpPWpGaD
Ifosfamide—CYP3A5—Metabolism—PTGS2—bone cancer	3.65e-06	0.000156	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—GSTP1—bone cancer	3.27e-06	0.00014	CbGpPWpGaD
Ifosfamide—CYP2C8—Metabolism—PTGS2—bone cancer	3.16e-06	0.000135	CbGpPWpGaD
Ifosfamide—CYP2C19—Metabolism—PTGS2—bone cancer	2.82e-06	0.00012	CbGpPWpGaD
Ifosfamide—CYP2C9—Metabolism—PTGS2—bone cancer	2.57e-06	0.00011	CbGpPWpGaD
Ifosfamide—CYP3A4—Metabolism—PTGS2—bone cancer	1.69e-06	7.24e-05	CbGpPWpGaD
